A Fully Automated Data Workflow for Quality Monitoring of Oligonucleotide Therapeutics

ASMS 2024, Anaheim, CA, USA
June 2, 2024

Oligonucleotide-based biotherapeutics can succeed in treating a diverse range of conditions for which a protein-based therapeutic may have less success. Given their many outstanding therapeutic characteristics (such as high specificity, functional diversity, and easy adjustment), they are rapidly emerging as an area of key interest across the biopharmaceutical industry. Although comparable to small-molecule pharmaceuticals, the complex structures and synthesis processes of oligonucleotides often lead to the generation of impurities and degradation products. Consequently, oligonucleotide therapeutics require stringent identity and quality control measures. We present a range of fully automated MS data processing, analysis, and reporting workflows enabling high-throughput identity testing and quality monitoring of oligonucleotide therapeutics.